bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapyIt’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its Share Xbluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapyhttps://pharmaphorum.com/news/bluebird-bio-baffled-after-nice-rejects/
NICE reverses stance on Celgene’s Revlimid for myeloma maintenanceNHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after Share XNICE reverses stance on Celgene’s Revlimid for myeloma maintenancehttps://pharmaphorum.com/news/nice-reverses-view-of-celgenes-revlimid-for-myeloma-maintenance/
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAJohnson & Johnson’s Janssen unit has filed a rolling submission for its multiple myeloma CAR-T ciltacabtagene autoleucel (cilta-cel) Share XChasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAhttps://pharmaphorum.com/news/chasing-bms-jj-files-bcma-car-t-for-multiple-myeloma-to-fda/
Bluebird trumpets long-term data from beta-thalassaemia gene therapybluebird bio has presented long-term data from its Zynteglo one-time gene therapy for the blood disorder beta-thalassaemia, as Share XBluebird trumpets long-term data from beta-thalassaemia gene therapyhttps://pharmaphorum.com/news/bluebird-trumpets-long-term-data-from-beta-thalassaemia-gene-therapy/
CTI wins over FDA to claim early review of myelofibrosis drugShares in US biotech CTI BioPharma have shot up after the FDA agreed to an accelerated review early Share XCTI wins over FDA to claim early review of myelofibrosis drughttps://pharmaphorum.com/news/cti-wins-over-fda-to-claim-early-review-of-myelofibrosis-drug/
Blank cheque company merger creates cancer specialist VinceraLifeSci Acquisition – a so-called ‘blank cheque’ company – has announced a $60 million merger with Vincera Pharma Share XBlank cheque company merger creates cancer specialist Vincerahttps://pharmaphorum.com/news/blank-cheque-company-merger-creates-cancer-specialist-vincera/
Clinical decision-making insights for haematologists and oncologistsClinical trial readouts continue to emerge despite countries’ lockdown policies, providing several decision-making challenges for healthcare professionals such Share XClinical decision-making insights for haematologists and oncologistshttps://pharmaphorum.com/views-analysis-digital/clinical-decision-making-insights-for-haematologists-and-oncologists/
Takeda’s bleeding disorder drug Veyvondi backed for NHS useNHS England has recommended that patients with von Willebrand disease (VWD) be treated with Takeda’s Veyvondi, making it Share XTakeda’s bleeding disorder drug Veyvondi backed for NHS usehttps://pharmaphorum.com/news/takedas-bleeding-disorder-drug-veyvondi-backed-for-nhs-use/
GSK moves further ahead in BCMA with EU okay for BlenrepGlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the Share XGSK moves further ahead in BCMA with EU okay for Blenrephttps://pharmaphorum.com/news/gsk-moves-further-ahead-in-bcma-with-eu-okay-for-blenrep/
